

October 29th, 2025

11:00 AM



Prof. Dr. Victor Deflon

University of Sao Paulo, Brazil

BACKGROUND

Victor Deflon holds a PhD in Chemistry from the University of Tübingen (1998).

He was a professor at the Chemistry Institute of the University of Brasília from 1999 to 2006. Since then, he has been a full professor at the Chemistry Institute of São Carlos, University of São Paulo, where he works primarily in the areas of preparative, structural, and medicinal inorganic chemistry, with an emphasis on the development of cancer chemotherapeutics and theranostics of nuclear medicine interest.

He is a principal investigator at the CancerThera Research, Innovation and Dissemination Center (CEPID) and a National Council for Scientific and Technological Development (CNPQ) level A researcher.

From the Laboratory to the Clinic: the Multi-Area Mission of CEPID CancerThera in the Development of Theranostics



Abstract

The lecture will provide an overview of the CancerThera Research Center (RIDC), one of Brazil's most innovative research centers, funded by FAPESP.

The main objective of this center is to develop cancer diagnosis and treatment through theranostics, an approach that combines diagnosis and therapy, if possible, in a single compound or a pair of analogs.

The lecture will address three fundamental pillars:

1. CancerThera's multi-area concept, with a deep integration of disciplines, in which chemists synthesize new compounds, cell biologists investigate the mechanisms of action, pharmacists optimize the efficacy and safety of the developed agents, and nuclear medicine physicians translate the discoveries into clinical practice, in a synergy that accelerates the translation from the bench to the patient's bedside;
2. The formation of the group and individual contributions, detailing the genesis of CancerThera, highlighting how experts were brought together around a mission, where individual contributions are cohesively combined to create a robust development pipeline, from the initial idea to potential human application;
3. Specific contributions in chelating agents, focusing on our work in developing high-performance bifunctional ligands, aiming to stably and safely bind a radionuclide to a compound that specifically targets the tumor.

C²TN Academy

SEMINARS · Workshops · Training sessions · Roundtable discussions

